SUPN Supernus Pharmaceuticals (SUPN) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001356576
Congress · 1
Insider buyers, 180 days
0
Funds added, last quarter
168
13F, latest reported quarter
Conversions, 180 days
5
Codes C/M, not in net · $0 priced
What the filings say about SUPN
Congress, 1 year
1 bought · 0 sold
Latest: purchase, 2026-03-03
Supernus Pharmaceuticals insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for SUPERNUS PHARMACEUTICALS, INC. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 22 earlier Form 4 trades (code P or S) here by this insider (22 sales), the last on Mar 17, 2026.
- The trade is 2.4% of the 17,044 shares held after it.
- 6 other insiders sold within 30 days.
- 168 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Sr. VP of IP, CSO Bhatt Padmanabh P. sold about $20.8K of SUPN on Mar 18, 2026; 6 other insiders sold within 30 days and 168 funds added in the latest 13F quarter.Context
- 22 earlier Form 4 trades (code P or S) here by this insider (22 sales), the last on Mar 17, 2026.
- The trade is 39.2% of the 17,456 shares held after it.
- 6 other insiders sold within 30 days.
- 168 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Sr. VP of IP, CSO Bhatt Padmanabh P. sold about $338.8K of SUPN on Mar 18, 2026; 6 other insiders sold within 30 days and 168 funds added in the latest 13F quarter.Context
- 20 earlier Form 4 trades (code P or S) here by this insider (20 sales), the last on Mar 16, 2026.
- The trade is 70.4% of the 39,334 shares held after it.
- 6 other insiders sold within 30 days.
- 168 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Sr. VP of IP, CSO Bhatt Padmanabh P. sold about $1.4M of SUPN on Mar 17, 2026; 6 other insiders sold within 30 days and 168 funds added in the latest 13F quarter.Context
- 20 earlier Form 4 trades (code P or S) here by this insider (20 sales), the last on Mar 16, 2026.
- The trade is 130.8% of the 17,044 shares held after it.
- 6 other insiders sold within 30 days.
- 168 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Sr. VP of IP, CSO Bhatt Padmanabh P. sold about $1.1M of SUPN on Mar 17, 2026; 6 other insiders sold within 30 days and 168 funds added in the latest 13F quarter.Context
- 18 earlier Form 4 trades (code P or S) here by this insider (18 sales), the last on Dec 18, 2025.
- The trade is 103.6% of the 32,930 shares held after it.
- 6 other insiders sold within 30 days.
- 168 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Sr. VP of IP, CSO Bhatt Padmanabh P. sold about $1.7M of SUPN on Mar 16, 2026; 6 other insiders sold within 30 days and 168 funds added in the latest 13F quarter.103 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
1 member bought in the last year
the lowest in Pharma & Biotech
Funds
168 funds bought in last quarter
more than 85% of Pharma & Biotech
Revenue
+8.6% year over year
more than 57% of Pharma & Biotech
Margin
-5.4% net margin
more than 68% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
9.6% of the float short (float per yahoo 2026-10-26) · 7.4 days to cover · settled 2026-09-30
more than 66% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch SUPN
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-21.6%12M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns SUPN: institutional holders (13F)
13F holdings, latest reported quarter
9,350,046 sh
$434.9M
3,853,212 sh
$179.2M
3,305,429 sh
$153.7M
2,646,201 sh
$123.1M
2,516,721 sh
$117.1M
Congress trades in SUPN
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Bought 2026-03-03 · disclosed 35 days later
$1,001 - $15,000
Bought 2025-12-11 · disclosed 32 days later
$1,001 - $15,000
Sold 2025-10-09 · disclosed 40 days later
$1,001 - $15,000
Bought 2025-03-24 · disclosed 14 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
SUPN planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
SUPN mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Third Avenue Small-Cap Value Fund
$7.0M position · as of 2026-07-31
3.2%
AdvisorShares Psychedelics ETF
$1.3M position · as of 2026-06-30
2.9%
Invesco Pharmaceuticals ETF
$11.5M position · as of 2026-07-31
2.4%
abrdn U.S. Small Cap Equity Fund
$9.3M position · as of 2026-07-31
2.4%
abrdn Focused U.S. Small Cap Active ETF
$225.9K position · as of 2026-07-31
2.3%
BRUCE FUND
$7.0M position · as of 2026-06-30
1.9%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
43 registered trials, 7 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
5
Phase 1
0 active
15
Phase 2
4 active
11
Phase 3
1 active
6
Phase 4
1 active
4
Not applicable
1 active
2
Multi-phase
0 active
What changed recently
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children Wi
2026-09-12 · Completion moved 2026-06 → 2028-01
Phase 4
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Jack Khattar
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2023
$13.3M
$13.5M
$1.8M
+22%
+19%
2022
$10.0M
$11.1M
$1.2M
+50%
+14%
2021
$8.1M
$7.9M
$979.0K
+23%
+26%
2020
$6.7M
$6.1M
$1.2M
+6%
+26%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 168 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade. Each figure is a federal filing, dated the day it went public.
SUPN financials
Revenue growth
+8.6%
XBRL, annual
Net margin
-5.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$830.4M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM SUPN
| FY Dec 2025 | $719.0M |
| FY Dec 2024 | $661.8M |
| FY Dec 2023 | $607.5M |
| FY Dec 2022 | $667.2M |
| FY Dec 2021 | $579.8M |
| Jun 2026 | $219.1M |
| Mar 2026 | $207.7M |
| Dec 2025 | $211.6M |
| Sep 2025 | $192.1M |
| Jun 2025 | $165.5M |
| Mar 2025 | $149.8M |
| Dec 2024 | $174.2M |
| Sep 2024 | $175.7M |
At each fiscal year end
Single quarter
Net margin, TTM
-13.2%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM SUPN
| FY Dec 2025 | -5.4% |
| FY Dec 2024 | +11.2% |
| FY Dec 2023 | +0.2% |
| FY Dec 2022 | +9.1% |
| FY Dec 2021 | +9.2% |
| Jun 2026 | -26.6% |
| Mar 2026 | -1.1% |
| Dec 2025 | -2.0% |
| Sep 2025 | -23.5% |
| Jun 2025 | +13.6% |
| Mar 2025 | -7.9% |
| Dec 2024 | +8.8% |
| Sep 2024 | +21.9% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$18.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM SUPN
| FY Dec 2025 | $46.0M |
| FY Dec 2024 | $171.2M |
| FY Dec 2023 | $110.5M |
| FY Dec 2022 | $116.4M |
| FY Dec 2021 | $125.2M |
| Jun 2026 | -$5.4M |
| Mar 2026 | $66.5M |
| Dec 2025 | $19.4M |
| Sep 2025 | -$61.8M |
| Jun 2025 | $58.1M |
| Mar 2025 | $30.3M |
| Dec 2024 | $44.2M |
| Sep 2024 | $53.3M |
At each fiscal year end
Single quarter
Debt to equity
0.39x
long-term 2022-09-30 (45 months older than the period end) plus current 2022-09-30 (45 months older than the period end); equity 2026-06-30
Debt to equity SUPN
| FY Dec 2025 | 0.38x |
| FY Dec 2024 | 0.39x |
| FY Dec 2023 | 0.44x |
| FY Dec 2022 | 0.45x |
| FY Dec 2021 | 0.46x |
| Jun 2026 | 0.39x |
| Mar 2026 | 0.37x |
| Dec 2025 | 0.38x |
| Sep 2025 | 0.38x |
| Jun 2025 | 0.38x |
| Mar 2025 | 0.39x |
| Dec 2024 | 0.39x |
| Sep 2024 | 0.40x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.05x
TTM operating cash flow over long-term 2022-09-30 (45 months older than the period end) plus current 2022-09-30 (45 months older than the period end)
Cash flow to debt SUPN
| FY Dec 2025 | 0.12x |
| FY Dec 2024 | 0.43x |
| FY Dec 2023 | 0.28x |
| FY Dec 2022 | 0.29x |
| FY Dec 2021 | 0.34x |
| Jun 2026 | 0.05x |
| Mar 2026 | 0.21x |
| Dec 2025 | 0.12x |
| Sep 2025 | 0.18x |
| Jun 2025 | 0.47x |
| Mar 2025 | 0.41x |
| Dec 2024 | 0.43x |
| Sep 2024 | 0.43x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-10.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity SUPN
| FY Dec 2025 | -3.7% |
| FY Dec 2024 | +7.6% |
| FY Dec 2023 | +0.1% |
| FY Dec 2022 | +7.1% |
| FY Dec 2021 | +6.8% |
| Jun 2026 | -10.5% |
| Mar 2026 | -2.8% |
| Dec 2025 | -3.7% |
| Sep 2025 | -1.9% |
| Jun 2025 | +6.4% |
| Mar 2025 | +6.3% |
| Dec 2024 | +7.6% |
| Sep 2024 | +6.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-7.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets SUPN
| FY Dec 2025 | -2.7% |
| FY Dec 2024 | +5.6% |
| FY Dec 2023 | +0.1% |
| FY Dec 2022 | +3.6% |
| FY Dec 2021 | +3.3% |
| Jun 2026 | -7.8% |
| Mar 2026 | -2.0% |
| Dec 2025 | -2.7% |
| Sep 2025 | -1.4% |
| Jun 2025 | +4.8% |
| Mar 2025 | +4.7% |
| Dec 2024 | +5.6% |
| Sep 2024 | +4.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital SUPN
| FY Dec 2025 | n/a |
| FY Dec 2024 | +4.7% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | +4.2% |
| FY Dec 2021 | +6.9% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | +3.8% |
| Mar 2025 | +3.9% |
| Dec 2024 | +4.7% |
| Sep 2024 | +3.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-12.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed SUPN
| FY Dec 2025 | -5.7% |
| FY Dec 2024 | +7.9% |
| FY Dec 2023 | -0.5% |
| FY Dec 2022 | +3.9% |
| FY Dec 2021 | +6.5% |
| Jun 2026 | -12.0% |
| Mar 2026 | -5.5% |
| Dec 2025 | -5.7% |
| Sep 2025 | -3.5% |
| Jun 2025 | +6.1% |
| Mar 2025 | +7.3% |
| Dec 2024 | +7.9% |
| Sep 2024 | +5.8% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing SUPN
| FY Dec 2025 | n/a |
| FY Dec 2024 | 27.39x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 34.97x |
| FY Dec 2021 | 29.76x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | 27.41x |
| Mar 2025 | 29.50x |
| Dec 2024 | 27.39x |
| Sep 2024 | 29.14x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$2.6B
market value at close 2026-10-26 on 2026-07-28 shares, plus long-term 2022-09-30 (45 months older than the period end) plus current 2022-09-30 (45 months older than the period end), minus cash 2026-06-30
Enterprise value SUPN
| FY Dec 2025 | $3.1B |
| FY Dec 2024 | $2.3B |
| FY Dec 2023 | $1.9B |
| FY Dec 2022 | $2.2B |
| FY Dec 2021 | $1.7B |
| Jun 2026 | $2.9B |
| Mar 2026 | $3.2B |
| Dec 2025 | $3.1B |
| Sep 2025 | $2.9B |
| Jun 2025 | $2.0B |
| Mar 2025 | $2.1B |
| Dec 2024 | $2.3B |
| Sep 2024 | $2.1B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+0.8%
TTM free cash flow over market value at close 2026-10-26
FCF yield SUPN
| FY Dec 2025 | +1.6% |
| FY Dec 2024 | +8.6% |
| FY Dec 2023 | +7.0% |
| FY Dec 2022 | +6.0% |
| FY Dec 2021 | +8.1% |
| Jun 2026 | +0.7% |
| Mar 2026 | +2.8% |
| Dec 2025 | +1.6% |
| Sep 2025 | +2.6% |
| Jun 2025 | +10.5% |
| Mar 2025 | +8.9% |
| Dec 2024 | +8.6% |
| Sep 2024 | +10.0% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing SUPN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 8.57x |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | 0.02x |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | 0.17x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $719.0M | $661.8M | $607.5M | $667.2M |
| Operating income | -$62.3M | $81.7M | -$5.3M | $46.1M |
| Net income | -$38.6M | $73.9M | $1.3M | $60.7M |
| EPS (diluted) | -0.68 | 1.32 | 0.02 | 1.04 |
| Operating cash flow | $47.3M | $172.0M | $111.1M | $116.8M |
| Cash | $128.4M | $69.3M | $75.1M | $93.1M |
SEC XBRL, fiscal years, as known on 2026-10-28
SUPN Stock Sonar score 5/7 axes
Find similar shapesCompareSUPN ranks highest on profitability (77th percentile) and growth (57th), and lowest on risk and compliance (28th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
SUPN filings, in plain words
Have members of Congress traded SUPN?
Yes. In the year to 2026-10-28, 1 House member disclosed buying SUPN and 0 House members disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2026-03-03.
Read the full summary
In the year to 2026-10-28, 1 member of Congress disclosed buying SUPN and 0 members disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2026-03-03. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
